Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levocetirizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | HRH2 | P25021 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | TEK | Q02763 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 3/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | DRD4 | P21917 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetirizine SCHEMBL41108 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL17800801 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL41107 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Levocetirizine SCHEMBL2255374 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL5520719 | 1.00 | HRH1 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Levocetirizine SCHEMBL4914 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Levocetirizine SCHEMBL5935097 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL13724610 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL4176 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 | |
| Cetirizine SCHEMBL2455487 | 0.99 | DRD3 (1.00) | HRH1DRD3USP2TDP1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 827 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119700684-A | Levocetirizine hydrochloride particles and preparation method thereof | 康芝药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240100043-A1 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | JDP THERAPEUTICS LLC (US) | 2024-03-28 | — | — | US | claimed |
| CN-116650426-A | Levocetirizine hydrochloride tablet and preparation method thereof | 山东新时代药业有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-219208146-U | Drug feeder for levocetirizine hydrochloride oral liquid drops | 厦门紫旭医药科技有限公司 | 2023-06-20 | — | — | CN | claimed |
| EP-3222279-B1 | ORAL PHARMACEUTICAL FORMULATION OF MONTELUKAST AND LEVOCETIRIZINE AND METHOD FOR ITS PRODUCTION | INVEST BIELANY SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2021-11-17 | — | — | EP | claimed |
| EP-3578981-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2021-10-27 | — | — | EP | claimed |
| US-20210251984-A1 | Pharmaceutical Compositions Comprising Levocetirizine | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-08-19 | — | — | US | claimed |
| WO-2021071728-A1 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | JDP THERAPEUTICS LLC (US) | 2021-04-15 | — | — | WO | claimed |
| US-20210100792-A1 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | ESTEVE PHARMACEUTICALS S.A. (ES) | 2021-04-08 | — | — | US | claimed |
| CN-1713912-A | Use of levocetirizine for treating persistent allergic rhinitis | UCB FARCHIM SA (CH) | 2005-12-28 | — | — | CN | claimed |
| EP-1569650-A1 | USE OF LEVOCETIRIZINE FOR THE TREATMENT OF PERSISTENT ALLERGIC RHINITIS | UCB FARCHIM S.A. (CH) | 2005-09-07 | — | — | EP | claimed |
| CN-1662515-A | Amorphous form of(-)-}2-}4-}(4-chlorophenyl)-phenyl methyl}-1-piperazinyl] ethoxy] acetic acid dihydrochloride (levocetririzine dihydrochloride) | REDDYS LAB LTD DR REDDYS LAB L (IN) | 2005-08-31 | — | — | CN | claimed |
| WO-2005077371-A1 | USE OF LEVOCETIRIZINE FOR THE PREPARATION OF A DRUG | UCB FARCHIM SA (CH) | 2005-08-25 | — | — | WO | claimed |
| US-20050038039-A1 | Mixture of 2-(4-(diphenylmethane)-1-piperazinyl)acetic acid compound and solid polyol | UCB, INC. | 2005-02-17 | — | — | US | claimed |
| EP-1467715-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE COMPOUNDS | UCB Farchim S.A. (CH) | 2004-10-20 | — | — | EP | claimed |
| US-20040132743-A1 | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) | DR. REDDY'S LABORATORIES LIMITED DR. REDDY'S LABORATORIES, INC. | 2004-07-08 | — | — | US | claimed |
| WO-2004050094-A1 | USE OF LEVOCETIRIZINE FOR THE TREATMENT OF PERSISTENT ALLERGIC RHINITIS | UCB FARCHIM S.A. (CH) | 2004-06-17 | — | — | WO | claimed |
| WO-2004000823-A1 | AMORPHOUS FORM OF(-)-}2-}4-}(4-CHLOROPHENYL)-PHENYL METHYL}-1-PIPERAZINYL] ETHOXY] ACETIC ACID DIHYDROCHLORIDE (LEVOCETRIRIZINE DIHYDROCHLORIDE) | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-12-31 | — | — | WO | claimed |
| WO-2003059328-A1 | FORMULATIONS | UCB FARCHIM, S.A. (CH) | 2003-07-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132743-A1 | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) | HRH4, HRH1, HRH2 | HRH1 2/4885DRD3 2293/4885USP2 261/4885 |
| US-20050038039-A1 | Mixture of 2-(4-(diphenylmethane)-1-piperazinyl)acetic acid compound and solid polyol | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ACP3, HDAC10 | HRH1 1090/4885DRD3 3061/4885USP2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.